Shares of Transcat, Inc. (NASDAQ:TRNS) have received an average broker rating score of 1.50 (Buy) from the two analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. Transcat’s rating score has declined by 12.8% in the last 90 days as a result of various analysts’ upgrades and downgrades.
Brokerages have set a one year consensus price target of $27.67 for the company and are expecting that the company will post $0.26 earnings per share for the current quarter, according to Zacks. Zacks has also assigned Transcat an industry rank of 16 out of 256 based on the ratings given to its competitors.
Separately, Zacks Investment Research cut Transcat from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 31st.
Transcat (NASDAQ:TRNS) last posted its earnings results on Wednesday, October 24th. The scientific and technical instruments company reported $0.20 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.16 by $0.04. Transcat had a net margin of 4.54% and a return on equity of 12.45%. The firm had revenue of $38.88 million during the quarter, compared to the consensus estimate of $38.00 million. As a group, equities research analysts forecast that Transcat will post 1 earnings per share for the current year.
In related news, Director John T. Smith sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 31st. The stock was sold at an average price of $10.30, for a total value of $30,900.00. Following the completion of the sale, the director now owns 42,166 shares in the company, valued at $434,309.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gary J. Haseley purchased 3,500 shares of the stock in a transaction that occurred on Tuesday, November 20th. The stock was purchased at an average price of $20.43 per share, with a total value of $71,505.00. Following the acquisition, the director now directly owns 20,150 shares of the company’s stock, valued at approximately $411,664.50. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 4,100 shares of company stock valued at $83,709 and sold 10,639 shares valued at $109,307. 8.80% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in TRNS. Thomson Horstmann & Bryant Inc. purchased a new stake in shares of Transcat in the third quarter valued at approximately $5,370,000. Wasatch Advisors Inc. purchased a new stake in shares of Transcat in the third quarter valued at approximately $5,121,000. Manatuck Hill Partners LLC purchased a new stake in shares of Transcat in the third quarter valued at approximately $1,143,000. Essex Investment Management Co. LLC purchased a new stake in shares of Transcat in the third quarter valued at approximately $1,127,000. Finally, EAM Investors LLC purchased a new stake in shares of Transcat in the third quarter valued at approximately $737,000. Hedge funds and other institutional investors own 57.83% of the company’s stock.
Transcat Company Profile
Transcat, Inc provides calibration and laboratory instrument services in North America and internationally. It operates in two segments, Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.
Further Reading: Determine Your Level of Risk Tolerance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Transcat Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transcat and related companies with MarketBeat.com's FREE daily email newsletter.